Piramal Pharma Solutions Highlights Strong Performance Across More Than 200 Customer Audits
Piramal Pharma Solutions reported successful outcomes from over 200 customer audits and 70 regulatory approvals in the past fiscal year. The company attributes this performance to its quality governance framework and digital transformation initiatives.
Why it matters
High audit success rates are critical for CDMOs to maintain global market access and demonstrate operational reliability in the pharmaceutical supply chain.
MUMBAI, India , June 22, 2026 /PRNewswire/ -- Piramal Pharma Solutions ("PPS"), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), today announced that it completed more than 200 customer audits and received over 70 approvals from regulatory agencies across its global network over the past fiscal year. The positive outcomes reflect the strength of the Company s long-range quality strategy and its ongoing commitment to scientific excellence and continuous improvement.
The content is a corporate press release summary focusing on operational metrics and quality standards.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in